You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameChloroquine
Accession NumberDB00608  (APRD00468)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionThe prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. [PubChem]
Structure
Thumb
Synonyms
Chloraquine
Chlorochin
Chlorochine
Chloroquina
Chloroquine
Chloroquinium
Chloroquinum
Cloroquina
N(4)-(7-chloro-4-Quinolinyl)-N(1),N(1)-diethyl-1,4-pentanediamine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aralentablet250 mgoralSanofi Synthelabo Canada Inc1951-12-312005-08-01Canada
Teva-chloroquinetablet250 mgoralTeva Canada Limited1968-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chloroquinetablet, coated500 mg/1oralGolden State Medical Supply, Inc.1999-09-17Not applicableUs
Chloroquinetablet, coated500 mg/1oralPd Rx Pharmaceuticals, Inc.1999-09-17Not applicableUs
Chloroquinetablet250 mg/1oralWest ward Pharmaceutical Corp1975-07-09Not applicableUs
Chloroquinetablet, coated500 mg/1oralCarilion Materials Management1999-09-17Not applicableUs
Chloroquinetablet250 mg/1oralGolden State Medical Supply, Inc.1975-07-09Not applicableUs
Chloroquinetablet, coated500 mg/1oralWest ward Pharmaceutical Corp1999-09-17Not applicableUs
Chloroquine Phosphatetablet250 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories, Inc.1974-12-11Not applicableUs
Chloroquine Phosphatetablet, film coated250 mg/1oralbryant ranch prepack2011-03-15Not applicableUs
Chloroquine Phosphatetablet, film coated500 mg/1oralPd Rx Pharmaceuticals, Inc.2011-03-15Not applicableUs
Chloroquine Phosphatetablet, film coated250 mg/1oralRanbaxy Pharmaceuticals Inc.2011-03-15Not applicableUs
Chloroquine Phosphatetablet500 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories, Inc.2005-11-01Not applicableUs
Chloroquine Phosphatetablet250 mg/1oralRising Pharmaceuticals, Inc.2011-07-01Not applicableUs
Chloroquine Phosphatetablet, film coated500 mg/1oralRanbaxy Pharmaceuticals Inc.2011-03-15Not applicableUs
Chloroquine Phosphatetablet, film coated500 mg/1oralbryant ranch prepack2011-03-15Not applicableUs
Chloroquine Phosphatetablet500 mg/1oralRising Pharmaceuticals, Inc.2011-07-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArtrichinNot Available
BemaphateNot Available
CapquinNot Available
MalarexActavis
Nivaquine BSanofi
ResoquineNot Available
ReumachlorNot Available
SanoquinNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Chloroquine diphosphate
ThumbNot applicableDBSALT001189
Chloroquine hydrochloride
ThumbNot applicableDBSALT001317
Chloroquine phosphate
Thumb
  • InChI Key: AEUAEICGCMSYCQ-UHFFFAOYNA-N
  • Monoisotopic Mass: 417.15842065
  • Average Mass: 417.867
DBSALT000025
Categories
UNII886U3H6UFF
CAS number54-05-7
WeightAverage: 319.872
Monoisotopic: 319.181525554
Chemical FormulaC18H26ClN3
InChI KeyInChIKey=WHTVZRBIWZFKQO-UHFFFAOYSA-N
InChI
InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)
IUPAC Name
7-chloro-N-[5-(diethylamino)pentan-2-yl]quinolin-4-amine
SMILES
CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminoquinolines and derivatives. These are organic compounds containing an amino group attached to a quinoline ring system.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassAminoquinolines and derivatives
Direct ParentAminoquinolines and derivatives
Alternative Parents
Substituents
  • Chloroquinoline
  • Aminoquinoline
  • Secondary aliphatic/aromatic amine
  • Aminopyridine
  • Benzenoid
  • Pyridine
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Secondary amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the suppressive treatment and for acute attacks of malaria due to P. vivax, P.malariae, P. ovale, and susceptible strains of P. falciparum, Second-line agent in treatment of Rheumatoid Arthritis
PharmacodynamicsChloroquine is the prototype anti malarial drug, most widely used to treat all types of malaria except for disease caused by chloroquine resistant Plasmodium falciparum. It is highly effective against erythrocytic forms of Plasmodium vivax, Plasmodium ovale and Plasmodium malariae, sensitive strains of Plasmodium falciparum and gametocytes of Plasmodium vivax. Being alkaline, the drug reaches high concentration within the food vacuoles of the parasite and raises its pH. It is found to induce rapid clumping of the pigment. Chloroquine inhibits the parasitic enzyme heme polymerase that converts the toxic heme into non-toxic hemazoin, thereby resulting in the accumulation of toxic heme within the parasite. It may also interfere with the biosynthesis of nucleic acids.
Mechanism of actionThe mechanism of plasmodicidal action of chloroquine is not completely certain. Like other quinoline derivatives, it is thought to inhibit heme polymerase activity. This results in accumulation of free heme, which is toxic to the parasites. nside red blood cells, the malarial parasite must degrade hemoglobin to acquire essential amino acids, which the parasite requires to construct its own protein and for energy metabolism. Digestion is carried out in a vacuole of the parasite cell. During this process, the parasite produces the toxic and soluble molecule heme. The heme moiety consists of a porphyrin ring called Fe(II)-protoporphyrin IX (FP). To avoid destruction by this molecule, the parasite biocrystallizes heme to form hemozoin, a non-toxic molecule. Hemozoin collects in the digestive vacuole as insoluble crystals. Chloroquine enters the red blood cell, inhabiting parasite cell, and digestive vacuole by simple diffusion. Chloroquine then becomes protonated (to CQ2+), as the digestive vacuole is known to be acidic (pH 4.7); chloroquine then cannot leave by diffusion. Chloroquine caps hemozoin molecules to prevent further biocrystallization of heme, thus leading to heme buildup. Chloroquine binds to heme (or FP) to form what is known as the FP-Chloroquine complex; this complex is highly toxic to the cell and disrupts membrane function. Action of the toxic FP-Chloroquine and FP results in cell lysis and ultimately parasite cell autodigestion. In essence, the parasite cell drowns in its own metabolic products.
Related Articles
AbsorptionCompletely absorbed from gastrointestinal tract
Volume of distributionNot Available
Protein binding~55% of the drug in the plasma is bound to nondiffusible plasma constituents
Metabolism

Hepatic (partially)

Route of eliminationExcretion of chloroquine is quite slow, but is increased by acidification of the urine.
Half life1-2 months
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Plasmodium
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9939
Blood Brain Barrier+0.7421
Caco-2 permeable+0.5804
P-glycoprotein substrateSubstrate0.8
P-glycoprotein inhibitor IInhibitor0.622
P-glycoprotein inhibitor IIInhibitor0.7773
Renal organic cation transporterInhibitor0.6046
CYP450 2C9 substrateNon-substrate0.8422
CYP450 2D6 substrateSubstrate0.8804
CYP450 3A4 substrateSubstrate0.6009
CYP450 1A2 substrateNon-inhibitor0.8586
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9218
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5496
Ames testAMES toxic0.9106
CarcinogenicityNon-carcinogens0.8374
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9547 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6959
hERG inhibition (predictor II)Inhibitor0.8293
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sanofi aventis us llc
  • Impax laboratories inc
  • Ipca laboratories ltd
  • Md pharmaceutical inc
  • Purepac pharmaceutical co
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
Tablet, coatedoral500 mg/1
Tabletoral250 mg/1
Tabletoral500 mg/1
Tablet, film coatedoral250 mg/1
Tablet, film coatedoral500 mg/1
Tabletoral250 mg
Prices
Unit descriptionCostUnit
Aralen 500 mg tablet7.85USD tablet
Aralen phosphate 500 mg tablet7.78USD tablet
Chloroquine ph 500 mg tablet5.64USD tablet
Chloroquine Phosphate 500 mg tablet5.42USD tablet
Chloroquine phosphate powdr4.29USD g
Plaquenil 200 mg tablet3.14USD tablet
Chloroquine Phosphate 250 mg tablet2.57USD tablet
Chloroquine ph 250 mg tablet2.49USD tablet
Novo-Chloroquine 250 mg Tablet0.35USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility10.6 mg/LNot Available
logP4.63HANSCH,C ET AL. (1995)
pKa10.1SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0175 mg/mLALOGPS
logP5.28ALOGPS
logP3.93ChemAxon
logS-4.3ALOGPS
pKa (Strongest Basic)10.32ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area28.16 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity96.42 m3·mol-1ChemAxon
Polarizability37.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.47 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-000i-9320000000-2663c398ede2e502ca34View in MoNA
References
Synthesis Reference

Andersag, H., Breitner, S.and Jung, H.; U S . Patent 2,233,970; March 4,1941; assigned to
Winthrop Chemical Company, Inc.

US2233970
General ReferencesNot Available
External Links
ATC CodesP01BA01
AHFS Codes
  • 08:30.08
PDB Entries
FDA labelDownload (153 KB)
MSDSDownload (74.9 KB)
Interactions
Drug Interactions
Drug
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Chloroquine.
AbciximabChloroquine may increase the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Chloroquine can be increased when it is combined with Abiraterone.
AcebutololChloroquine may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Chloroquine is combined with Aceclofenac.
AcenocoumarolChloroquine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Chloroquine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Chloroquine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Chloroquine.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Chloroquine.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Chloroquine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Chloroquine.
Agalsidase betaThe therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Chloroquine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Chloroquine.
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Chloroquine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Chloroquine.
Alendronic acidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Alendronic acid.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Chloroquine.
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Chloroquine.
AliskirenChloroquine may decrease the antihypertensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Chloroquine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Chloroquine.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Chloroquine.
AlprenololChloroquine may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Chloroquine.
Aluminum hydroxideThe serum concentration of Chloroquine can be decreased when it is combined with Aluminum hydroxide.
Aluminum phosphateThe serum concentration of Chloroquine can be decreased when it is combined with Aluminum phosphate.
AmantadineAmantadine may increase the QTc-prolonging activities of Chloroquine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Chloroquine.
AmikacinChloroquine may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideChloroquine may decrease the antihypertensive activities of Amiloride.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Chloroquine.
AmiodaroneChloroquine may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Chloroquine can be decreased when combined with Amiodarone.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Chloroquine.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Chloroquine.
AmodiaquineThe serum concentration of Chloroquine can be decreased when it is combined with Amodiaquine.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Chloroquine.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Chloroquine.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Chloroquine.
AmpicillinThe serum concentration of Ampicillin can be decreased when it is combined with Chloroquine.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Chloroquine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Chloroquine.
AnagrelideChloroquine may increase the QTc-prolonging activities of Anagrelide.
AncrodChloroquine may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Antipyrine.
Antithrombin III humanChloroquine may increase the anticoagulant activities of Antithrombin III human.
ApixabanChloroquine may increase the anticoagulant activities of Apixaban.
ApomorphineApomorphine may increase the QTc-prolonging activities of Chloroquine.
ApremilastThe risk or severity of adverse effects can be increased when Chloroquine is combined with Apremilast.
AprepitantThe serum concentration of Chloroquine can be increased when it is combined with Aprepitant.
AprindineThe metabolism of Aprindine can be decreased when combined with Chloroquine.
ArdeparinChloroquine may increase the anticoagulant activities of Ardeparin.
ArformoterolArformoterol may increase the QTc-prolonging activities of Chloroquine.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Chloroquine.
ArgatrobanChloroquine may increase the anticoagulant activities of Argatroban.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Chloroquine.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Chloroquine.
ArotinololChloroquine may decrease the antihypertensive activities of Arotinolol.
ArsenamideThe serum concentration of Arsenamide can be decreased when it is combined with Chloroquine.
Arsenic trioxideChloroquine may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Chloroquine.
ArtemetherChloroquine may increase the QTc-prolonging activities of Artemether.
AsenapineChloroquine may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Chloroquine.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Chloroquine.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Chloroquine.
AtenololChloroquine may decrease the antihypertensive activities of Atenolol.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Chloroquine.
AtomoxetineThe metabolism of Atomoxetine can be decreased when combined with Chloroquine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Chloroquine.
AzapropazoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Chloroquine.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Chloroquine.
BalsalazideChloroquine may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Chloroquine.
BecaplerminChloroquine may increase the anticoagulant activities of Becaplermin.
BedaquilineChloroquine may increase the QTc-prolonging activities of Bedaquiline.
BefunololChloroquine may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Chloroquine.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Chloroquine.
BenoxaprofenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Benoxaprofen.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Chloroquine.
BenzimidazoleThe serum concentration of Benzimidazole can be decreased when it is combined with Chloroquine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Chloroquine.
BepridilThe metabolism of Bepridil can be decreased when combined with Chloroquine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Chloroquine.
BetaxololChloroquine may decrease the antihypertensive activities of Betaxolol.
BetaxololThe metabolism of Chloroquine can be decreased when combined with Betaxolol.
BevantololChloroquine may decrease the antihypertensive activities of Bevantolol.
BexaroteneThe serum concentration of Chloroquine can be decreased when it is combined with Bexarotene.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Chloroquine.
Bismuth SubcitrateThe serum concentration of Chloroquine can be decreased when it is combined with Bismuth Subcitrate.
BisoprololChloroquine may decrease the antihypertensive activities of Bisoprolol.
BithionolThe serum concentration of Bithionol can be decreased when it is combined with Chloroquine.
BivalirudinChloroquine may increase the anticoagulant activities of Bivalirudin.
BoceprevirThe metabolism of Chloroquine can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Chloroquine.
BopindololChloroquine may decrease the antihypertensive activities of Bopindolol.
BortezomibBortezomib may increase the QTc-prolonging activities of Chloroquine.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Chloroquine.
BosentanThe serum concentration of Chloroquine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Chloroquine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chloroquine.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Chloroquine.
BromfenacThe risk or severity of adverse effects can be increased when Chloroquine is combined with Bromfenac.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Chloroquine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Chloroquine.
BufuralolChloroquine may decrease the antihypertensive activities of Bufuralol.
BumetanideChloroquine may decrease the diuretic activities of Bumetanide.
BunamidineThe serum concentration of Bunamidine can be decreased when it is combined with Chloroquine.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Chloroquine.
BupranololChloroquine may decrease the antihypertensive activities of Bupranolol.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Chloroquine.
BupropionThe metabolism of Bupropion can be decreased when combined with Chloroquine.
BuserelinBuserelin may increase the QTc-prolonging activities of Chloroquine.
BuspironeThe metabolism of Buspirone can be decreased when combined with Chloroquine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Chloroquine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Chloroquine.
Calcium carbonateThe serum concentration of Chloroquine can be decreased when it is combined with Calcium carbonate.
CambendazoleThe serum concentration of Cambendazole can be decreased when it is combined with Chloroquine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Chloroquine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Chloroquine.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Chloroquine.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Chloroquine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Chloroquine.
CaptoprilThe metabolism of Captopril can be decreased when combined with Chloroquine.
CarbamazepineThe metabolism of Chloroquine can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Chloroquine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Chloroquine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Chloroquine.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Chloroquine.
CarprofenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Carprofen.
CarteololChloroquine may decrease the antihypertensive activities of Carteolol.
CarvedilolChloroquine may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Chloroquine.
CeliprololChloroquine may decrease the antihypertensive activities of Celiprolol.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Chloroquine.
CeritinibThe serum concentration of Chloroquine can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Chloroquine.
CertoparinChloroquine may increase the anticoagulant activities of Certoparin.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Chloroquine.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Chloroquine.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Chloroquine.
ChloroxylenolThe serum concentration of Chloroxylenol can be decreased when it is combined with Chloroquine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Chloroquine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Chloroquine.
ChlorpromazineThe metabolism of Chloroquine can be decreased when combined with Chlorpromazine.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Chloroquine.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Chloroquine.
CholecalciferolThe metabolism of Chloroquine can be decreased when combined with Cholecalciferol.
CholestyramineCholestyramine can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Chloroquine.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Chloroquine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Chloroquine.
CimetidineThe metabolism of Chloroquine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Chloroquine can be decreased when combined with Cinacalcet.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Chloroquine.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Chloroquine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Chloroquine.
CisaprideChloroquine may increase the QTc-prolonging activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Chloroquine.
CitalopramChloroquine may increase the QTc-prolonging activities of Citalopram.
CitalopramThe metabolism of Chloroquine can be decreased when combined with Citalopram.
Citric AcidChloroquine may increase the anticoagulant activities of Citric Acid.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Chloroquine.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Chloroquine.
ClemastineThe metabolism of Chloroquine can be decreased when combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Chloroquine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Chloroquine.
ClobazamThe metabolism of Chloroquine can be decreased when combined with Clobazam.
ClodronateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Clodronate.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Chloroquine.
ClomipramineClomipramine may increase the QTc-prolonging activities of Chloroquine.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Chloroquine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Chloroquine.
ClonixinThe risk or severity of adverse effects can be increased when Chloroquine is combined with Clonixin.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Chloroquine.
ClopidogrelThe metabolism of Chloroquine can be decreased when combined with Clopidogrel.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Chloroquine.
ClorsulonThe serum concentration of Clorsulon can be decreased when it is combined with Chloroquine.
ClotrimazoleThe metabolism of Chloroquine can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Chloroquine.
ClozapineThe metabolism of Chloroquine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Chloroquine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Chloroquine.
CocaineThe metabolism of Chloroquine can be decreased when combined with Cocaine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Chloroquine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Chloroquine.
ColesevelamColesevelam can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.
ConivaptanThe serum concentration of Chloroquine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Chloroquine.
CoumaphosThe serum concentration of Coumaphos can be decreased when it is combined with Chloroquine.
CrizotinibThe metabolism of Chloroquine can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Chloroquine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Chloroquine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Chloroquine.
CyclosporineThe metabolism of Chloroquine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Chloroquine.
D-LimoneneThe risk or severity of adverse effects can be increased when Chloroquine is combined with D-Limonene.
Dabigatran etexilateChloroquine may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Chloroquine.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Chloroquine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Chloroquine.
DalteparinChloroquine may increase the anticoagulant activities of Dalteparin.
DanaparoidChloroquine may increase the anticoagulant activities of Danaparoid.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Chloroquine.
DapsoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Dapsone.
DarifenacinThe metabolism of Chloroquine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Chloroquine can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Chloroquine.
DasatinibThe serum concentration of Chloroquine can be increased when it is combined with Dasatinib.
DaunorubicinChloroquine may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Chloroquine.
DeferasiroxThe serum concentration of Chloroquine can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Chloroquine is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Chloroquine.
DelavirdineThe metabolism of Chloroquine can be decreased when combined with Delavirdine.
DesfluraneDesflurane may increase the QTc-prolonging activities of Chloroquine.
DesipramineDesipramine may increase the QTc-prolonging activities of Chloroquine.
DesipramineThe metabolism of Desipramine can be decreased when combined with Chloroquine.
DesirudinChloroquine may increase the anticoagulant activities of Desirudin.
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Chloroquine.
DesmopressinThe risk or severity of adverse effects can be increased when Chloroquine is combined with Desmopressin.
DexamethasoneThe serum concentration of Chloroquine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Chloroquine.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Chloroquine.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Chloroquine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Chloroquine.
DextranChloroquine may increase the anticoagulant activities of Dextran.
Dextran 40Chloroquine may increase the anticoagulant activities of Dextran 40.
Dextran 70Chloroquine may increase the anticoagulant activities of Dextran 70.
Dextran 75Chloroquine may increase the anticoagulant activities of Dextran 75.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Chloroquine.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Chloroquine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Chloroquine.
DichlorvosThe serum concentration of Dichlorvos can be decreased when it is combined with Chloroquine.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Chloroquine.
DicoumarolChloroquine may increase the anticoagulant activities of Dicoumarol.
DiethylcarbamazineThe serum concentration of Diethylcarbamazine can be decreased when it is combined with Chloroquine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Chloroquine.
DiflunisalThe risk or severity of adverse effects can be increased when Chloroquine is combined with Diflunisal.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Chloroquine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Chloroquine.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Chloroquine.
DihydroergotamineThe metabolism of Chloroquine can be decreased when combined with Dihydroergotamine.
DihydrostreptomycinChloroquine may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Chloroquine.
DiltiazemThe metabolism of Chloroquine can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Chloroquine.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Chloroquine.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Chloroquine.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Chloroquine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Chloroquine.
DisopyramideChloroquine may increase the QTc-prolonging activities of Disopyramide.
DithiazanineThe serum concentration of Dithiazanine can be decreased when it is combined with Chloroquine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Chloroquine.
DofetilideChloroquine may increase the QTc-prolonging activities of Dofetilide.
DolasetronDolasetron may increase the QTc-prolonging activities of Chloroquine.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Chloroquine.
DomperidoneChloroquine may increase the QTc-prolonging activities of Domperidone.
DonepezilThe metabolism of Donepezil can be decreased when combined with Chloroquine.
DopamineThe metabolism of Dopamine can be decreased when combined with Chloroquine.
DoramectinThe serum concentration of Doramectin can be decreased when it is combined with Chloroquine.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Chloroquine.
DoxepinDoxepin may increase the QTc-prolonging activities of Chloroquine.
DoxepinThe metabolism of Doxepin can be decreased when combined with Chloroquine.
DoxorubicinChloroquine may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DoxycyclineThe metabolism of Chloroquine can be decreased when combined with Doxycycline.
DronedaroneChloroquine may increase the QTc-prolonging activities of Dronedarone.
DronedaroneThe metabolism of Chloroquine can be decreased when combined with Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Chloroquine.
DrospirenoneChloroquine may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Chloroquine is combined with Droxicam.
DuloxetineThe metabolism of Chloroquine can be decreased when combined with Duloxetine.
Edetic AcidChloroquine may increase the anticoagulant activities of Edetic Acid.
EdoxabanChloroquine may increase the anticoagulant activities of Edoxaban.
EfavirenzThe serum concentration of Chloroquine can be decreased when it is combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Chloroquine.
EliglustatChloroquine may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Chloroquine can be decreased when combined with Eliglustat.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Chloroquine.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Chloroquine.
EncainideThe metabolism of Encainide can be decreased when combined with Chloroquine.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Chloroquine.
EnoxaparinChloroquine may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Chloroquine can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Chloroquine.
EpirizoleThe risk or severity of adverse effects can be increased when Chloroquine is combined with Epirizole.
EpirubicinChloroquine may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneChloroquine may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Chloroquine.
EprinomectinThe serum concentration of Eprinomectin can be decreased when it is combined with Chloroquine.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Chloroquine.
EribulinEribulin may increase the QTc-prolonging activities of Chloroquine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Chloroquine.
ErythromycinThe metabolism of Chloroquine can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Chloroquine.
EscitalopramChloroquine may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Chloroquine can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Chloroquine.
EsmololChloroquine may decrease the antihypertensive activities of Esmolol.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Chloroquine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Chloroquine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Chloroquine.
Etacrynic acidChloroquine may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Chloroquine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Chloroquine.
Ethyl biscoumacetateChloroquine may increase the anticoagulant activities of Ethyl biscoumacetate.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Chloroquine.
Etidronic acidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Chloroquine is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Etofenamate.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Chloroquine.
EtoricoxibThe risk or severity of adverse effects can be increased when Chloroquine is combined with Etoricoxib.
EtravirineThe serum concentration of Chloroquine can be decreased when it is combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Chloroquine is combined with Evening primrose oil.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Chloroquine.
exisulindThe risk or severity of adverse effects can be increased when Chloroquine is combined with exisulind.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Chloroquine.
EzogabineEzogabine may increase the QTc-prolonging activities of Chloroquine.
FamotidineFamotidine may increase the QTc-prolonging activities of Chloroquine.
FebantelThe serum concentration of Febantel can be decreased when it is combined with Chloroquine.
FelbamateFelbamate may increase the QTc-prolonging activities of Chloroquine.
FelodipineThe metabolism of Chloroquine can be decreased when combined with Felodipine.
FenbendazoleThe serum concentration of Fenbendazole can be decreased when it is combined with Chloroquine.
FenbufenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Chloroquine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chloroquine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Chloroquine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Chloroquine.
FingolimodFingolimod may increase the QTc-prolonging activities of Chloroquine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Chloroquine.
FlecainideFlecainide may increase the QTc-prolonging activities of Chloroquine.
FlecainideThe metabolism of Flecainide can be decreased when combined with Chloroquine.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Chloroquine.
FlubendazoleThe serum concentration of Flubendazole can be decreased when it is combined with Chloroquine.
FluconazoleFluconazole may increase the QTc-prolonging activities of Chloroquine.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Chloroquine.
FlunixinThe risk or severity of adverse effects can be increased when Chloroquine is combined with Flunixin.
FluoxetineChloroquine may increase the QTc-prolonging activities of Fluoxetine.
FluoxetineThe metabolism of Chloroquine can be decreased when combined with Fluoxetine.
FlupentixolChloroquine may increase the QTc-prolonging activities of Flupentixol.
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Chloroquine.
FlurbiprofenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Flurbiprofen.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Chloroquine.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Chloroquine.
FluvoxamineThe metabolism of Chloroquine can be decreased when combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Chloroquine.
Fondaparinux sodiumChloroquine may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Chloroquine.
FormoterolFormoterol may increase the QTc-prolonging activities of Chloroquine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Chloroquine.
FosamprenavirThe metabolism of Chloroquine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Chloroquine can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Chloroquine.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Chloroquine.
FosphenytoinThe metabolism of Chloroquine can be increased when combined with Fosphenytoin.
FramycetinChloroquine may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideChloroquine may decrease the diuretic activities of Furosemide.
Fusidic AcidThe serum concentration of Chloroquine can be increased when it is combined with Fusidic Acid.
Gadobenic acidChloroquine may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineGalantamine may increase the QTc-prolonging activities of Chloroquine.
GalantamineThe metabolism of Galantamine can be decreased when combined with Chloroquine.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Chloroquine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Chloroquine.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Chloroquine.
GemfibrozilThe metabolism of Chloroquine can be decreased when combined with Gemfibrozil.
GemifloxacinChloroquine may increase the QTc-prolonging activities of Gemifloxacin.
GentamicinChloroquine may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
GoserelinGoserelin may increase the QTc-prolonging activities of Chloroquine.
GranisetronGranisetron may increase the QTc-prolonging activities of Chloroquine.
GranisetronThe metabolism of Granisetron can be decreased when combined with Chloroquine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Chloroquine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Chloroquine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Chloroquine.
HaloperidolThe risk or severity of adverse effects can be increased when Chloroquine is combined with Haloperidol.
HaloperidolThe metabolism of Chloroquine can be decreased when combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Chloroquine.
HeparinChloroquine may increase the anticoagulant activities of Heparin.
HexylresorcinolThe serum concentration of Hexylresorcinol can be decreased when it is combined with Chloroquine.
HirulogChloroquine may increase the anticoagulant activities of Hirulog.
HistrelinHistrelin may increase the QTc-prolonging activities of Chloroquine.
HMPL-004The risk or severity of adverse effects can be increased when Chloroquine is combined with HMPL-004.
HydralazineChloroquine may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Chloroquine.
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Chloroquine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Chloroquine.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Chloroquine.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Chloroquine.
HydroxychloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Hydroxychloroquine.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Chloroquine.
Hygromycin BChloroquine may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Ibandronate.
IbandronateIbandronate may increase the QTc-prolonging activities of Chloroquine.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Chloroquine.
IbuprofenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Chloroquine is combined with Ibuproxam.
IbutilideChloroquine may increase the QTc-prolonging activities of Ibutilide.
IcatibantThe risk or severity of adverse effects can be increased when Chloroquine is combined with Icatibant.
IdarubicinChloroquine may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IdelalisibThe serum concentration of Chloroquine can be increased when it is combined with Idelalisib.
IloperidoneChloroquine may increase the QTc-prolonging activities of Iloperidone.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Chloroquine.
ImatinibThe metabolism of Chloroquine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Chloroquine.
ImipramineImipramine may increase the QTc-prolonging activities of Chloroquine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Chloroquine.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Chloroquine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Chloroquine.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Chloroquine.
IndapamideIndapamide may increase the QTc-prolonging activities of Chloroquine.
IndenololChloroquine may decrease the antihypertensive activities of Indenolol.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Chloroquine.
IndinavirThe metabolism of Chloroquine can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Chloroquine.
IndoprofenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Indoprofen.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Chloroquine.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Chloroquine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Chloroquine.
IsavuconazoniumThe metabolism of Chloroquine can be decreased when combined with Isavuconazonium.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Chloroquine.
IsoniazidThe metabolism of Chloroquine can be decreased when combined with Isoniazid.
IsoxicamThe risk or severity of adverse effects can be increased when Chloroquine is combined with Isoxicam.
IsradipineIsradipine may increase the QTc-prolonging activities of Chloroquine.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Chloroquine.
IvabradineIvabradine may increase the QTc-prolonging activities of Chloroquine.
IvacaftorThe serum concentration of Chloroquine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Chloroquine.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Chloroquine.
KanamycinChloroquine may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KaolinThe serum concentration of Chloroquine can be decreased when it is combined with Kaolin.
KebuzoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Kebuzone.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Chloroquine.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Chloroquine.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Chloroquine.
KetoprofenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Chloroquine.
LabetalolChloroquine may decrease the antihypertensive activities of Labetalol.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Chloroquine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Chloroquine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Chloroquine.
Lanthanum carbonateThe serum concentration of Chloroquine can be decreased when it is combined with Lanthanum carbonate.
LapatinibLapatinib may increase the QTc-prolonging activities of Chloroquine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Chloroquine.
LeflunomideThe risk or severity of adverse effects can be increased when Chloroquine is combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Chloroquine.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Chloroquine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Chloroquine.
LepirudinChloroquine may increase the anticoagulant activities of Lepirudin.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Chloroquine.
LevamisoleThe serum concentration of Levamisole can be decreased when it is combined with Chloroquine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Chloroquine.
LevobunololChloroquine may decrease the antihypertensive activities of Levobunolol.
LevodopaThe metabolism of Levodopa can be decreased when combined with Chloroquine.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Chloroquine.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Chloroquine.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Chloroquine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Chloroquine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Chloroquine.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Chloroquine.
LisurideThe metabolism of Lisuride can be decreased when combined with Chloroquine.
LithiumThe serum concentration of Lithium can be increased when it is combined with Chloroquine.
LithiumLithium may increase the QTc-prolonging activities of Chloroquine.
LomustineThe metabolism of Lomustine can be decreased when combined with Chloroquine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Chloroquine.
LopinavirChloroquine may increase the QTc-prolonging activities of Lopinavir.
LopinavirThe metabolism of Chloroquine can be decreased when combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Chloroquine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Chloroquine.
LornoxicamThe risk or severity of adverse effects can be increased when Chloroquine is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Chloroquine.
LosartanThe serum concentration of Losartan can be increased when it is combined with Chloroquine.
LovastatinThe metabolism of Chloroquine can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Chloroquine.
LucanthoneThe serum concentration of Lucanthone can be decreased when it is combined with Chloroquine.
LuliconazoleThe serum concentration of Chloroquine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Chloroquine can be increased when it is combined with Lumacaftor.
LumefantrineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Lumefantrine.
LumefantrineThe metabolism of Chloroquine can be decreased when combined with Lumefantrine.
LumiracoxibThe risk or severity of adverse effects can be increased when Chloroquine is combined with Lumiracoxib.
MagaldrateThe serum concentration of Chloroquine can be decreased when it is combined with Magaldrate.
Magnesium carbonateThe serum concentration of Chloroquine can be decreased when it is combined with Magnesium carbonate.
Magnesium hydroxideThe serum concentration of Chloroquine can be decreased when it is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Chloroquine can be decreased when it is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Magnesium salicylate.
Magnesium TrisilicateThe serum concentration of Chloroquine can be decreased when it is combined with Magnesium Trisilicate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Chloroquine.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Chloroquine.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Chloroquine.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Chloroquine.
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Chloroquine.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mefenamic acid.
MefloquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mefloquine.
MefloquineMefloquine may increase the QTc-prolonging activities of Chloroquine.
MeloxicamThe risk or severity of adverse effects can be increased when Chloroquine is combined with Meloxicam.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Chloroquine.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Chloroquine.
MesalazineChloroquine may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Chloroquine.
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Chloroquine.
MetamizoleThe risk or severity of adverse effects can be increased when Chloroquine is combined with Metamizole.
MethadoneThe metabolism of Chloroquine can be decreased when combined with Methadone.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Chloroquine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Chloroquine.
MethotrimeprazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Chloroquine.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Chloroquine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Chloroquine.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Chloroquine.
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Chloroquine.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Chloroquine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Chloroquine.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Chloroquine.
MetipranololChloroquine may decrease the antihypertensive activities of Metipranolol.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Chloroquine.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Chloroquine.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Chloroquine.
MetoprololChloroquine may decrease the antihypertensive activities of Metoprolol.
MetoprololThe metabolism of Chloroquine can be decreased when combined with Metoprolol.
MetrizamideChloroquine may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Chloroquine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Chloroquine.
MianserinThe metabolism of Mianserin can be decreased when combined with Chloroquine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Chloroquine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Chloroquine.
Milbemycin oximeThe serum concentration of Milbemycin oxime can be decreased when it is combined with Chloroquine.
MinaprineThe metabolism of Minaprine can be decreased when combined with Chloroquine.
MirabegronMirabegron may increase the QTc-prolonging activities of Chloroquine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Chloroquine.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Chloroquine.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Chloroquine.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Chloroquine.
MitotaneThe serum concentration of Chloroquine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Chloroquine.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Chloroquine.
ModafinilThe serum concentration of Chloroquine can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Chloroquine.
MorantelThe serum concentration of Morantel can be decreased when it is combined with Chloroquine.
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Chloroquine.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Chloroquine.
MorphineThe serum concentration of Morphine can be increased when it is combined with Chloroquine.
MoxidectinThe serum concentration of Moxidectin can be decreased when it is combined with Chloroquine.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Chloroquine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Chloroquine.
NadololChloroquine may decrease the antihypertensive activities of Nadolol.
NadroparinChloroquine may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Chloroquine can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Naftifine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Chloroquine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Chloroquine.
NaproxenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Naproxen.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Chloroquine.
NCX 4016The risk or severity of adverse effects can be increased when Chloroquine is combined with NCX 4016.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Chloroquine.
NefazodoneThe metabolism of Chloroquine can be decreased when combined with Nefazodone.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Chloroquine.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Chloroquine.
NeomycinChloroquine may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Chloroquine is combined with Nepafenac.
NetilmicinChloroquine may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NetupitantThe serum concentration of Chloroquine can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Chloroquine.
NevirapineThe metabolism of Chloroquine can be decreased when combined with Nevirapine.
NicardipineNicardipine may increase the QTc-prolonging activities of Chloroquine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Chloroquine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Chloroquine.
NiclosamideThe serum concentration of Niclosamide can be decreased when it is combined with Chloroquine.
NicotineThe metabolism of Nicotine can be decreased when combined with Chloroquine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Chloroquine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Niflumic Acid.
NilotinibChloroquine may increase the QTc-prolonging activities of Nilotinib.
NilotinibThe metabolism of Chloroquine can be decreased when combined with Nilotinib.
NimesulideThe risk or severity of adverse effects can be increased when Chloroquine is combined with Nimesulide.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Chloroquine.
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Chloroquine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Chloroquine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Chloroquine.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Chloroquine.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Chloroquine.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Chloroquine.
OctreotideOctreotide may increase the QTc-prolonging activities of Chloroquine.
OfloxacinChloroquine may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Chloroquine.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Chloroquine.
OlaparibThe metabolism of Chloroquine can be decreased when combined with Olaparib.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Chloroquine.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Chloroquine.
OlopatadineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Olopatadine.
OlsalazineChloroquine may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Chloroquine.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Chloroquine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Chloroquine.
OndansetronOndansetron may increase the QTc-prolonging activities of Chloroquine.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Chloroquine.
OrgoteinThe risk or severity of adverse effects can be increased when Chloroquine is combined with Orgotein.
OsimertinibThe serum concentration of Chloroquine can be increased when it is combined with Osimertinib.
OtamixabanChloroquine may increase the anticoagulant activities of Otamixaban.
OuabainThe serum concentration of Ouabain can be increased when it is combined with Chloroquine.
OxamniquineThe serum concentration of Oxamniquine can be decreased when it is combined with Chloroquine.
OxaprozinThe risk or severity of adverse effects can be increased when Chloroquine is combined with Oxaprozin.
OxfendazoleThe serum concentration of Oxfendazole can be decreased when it is combined with Chloroquine.
OxibendazoleThe serum concentration of Oxibendazole can be decreased when it is combined with Chloroquine.
OxprenololChloroquine may decrease the antihypertensive activities of Oxprenolol.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Chloroquine.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Chloroquine.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Oxyphenbutazone.
OxytocinOxytocin may increase the QTc-prolonging activities of Chloroquine.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Chloroquine.
PalbociclibThe serum concentration of Chloroquine can be increased when it is combined with Palbociclib.
PaliperidoneChloroquine may increase the QTc-prolonging activities of Paliperidone.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Chloroquine.
PamidronateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Pamidronate.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Chloroquine.
PanobinostatThe metabolism of Chloroquine can be decreased when combined with Panobinostat.
ParecoxibThe risk or severity of adverse effects can be increased when Chloroquine is combined with Parecoxib.
ParomomycinChloroquine may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
ParoxetineParoxetine may increase the QTc-prolonging activities of Chloroquine.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Chloroquine.
PasireotidePasireotide may increase the QTc-prolonging activities of Chloroquine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Chloroquine.
PazopanibPazopanib may increase the QTc-prolonging activities of Chloroquine.
Peginterferon alfa-2bThe serum concentration of Chloroquine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololChloroquine may decrease the antihypertensive activities of Penbutolol.
PentamidinePentamidine may increase the QTc-prolonging activities of Chloroquine.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Chloroquine.
PentobarbitalThe metabolism of Chloroquine can be increased when combined with Pentobarbital.
Pentosan PolysulfateChloroquine may increase the anticoagulant activities of Pentosan Polysulfate.
PerflutrenPerflutren may increase the QTc-prolonging activities of Chloroquine.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Chloroquine.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Chloroquine.
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Chloroquine.
PethidineThe metabolism of Pethidine can be decreased when combined with Chloroquine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Chloroquine.
PhenforminThe metabolism of Phenformin can be decreased when combined with Chloroquine.
PhenindioneChloroquine may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Chloroquine can be increased when combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Chloroquine.
PhenprocoumonChloroquine may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Phenylbutazone.
PhenytoinThe metabolism of Chloroquine can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Chloroquine.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Chloroquine.
PimozideChloroquine may increase the QTc-prolonging activities of Pimozide.
PindololChloroquine may decrease the antihypertensive activities of Pindolol.
PioglitazoneThe metabolism of Chloroquine can be decreased when combined with Pioglitazone.
PiperazineThe serum concentration of Piperazine can be decreased when it is combined with Chloroquine.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Chloroquine.
PiretanideChloroquine may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Chloroquine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Chloroquine.
PlicamycinChloroquine may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Chloroquine.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Chloroquine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Chloroquine.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Chloroquine.
PractololChloroquine may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Chloroquine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Chloroquine.
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Chloroquine.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Chloroquine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Chloroquine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Chloroquine.
PrilocaineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Prilocaine.
PrimaquineThe serum concentration of Chloroquine can be decreased when it is combined with Primaquine.
PrimaquineChloroquine may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe metabolism of Chloroquine can be increased when combined with Primidone.
ProbenecidThe serum concentration of Chloroquine can be increased when it is combined with Probenecid.
ProcainamideChloroquine may increase the QTc-prolonging activities of Procainamide.
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Chloroquine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Chloroquine.
PromazineThe serum concentration of Promazine can be increased when it is combined with Chloroquine.
PromazineThe metabolism of Chloroquine can be decreased when combined with Promazine.
PromethazineThe serum concentration of Promethazine can be increased when it is combined with Chloroquine.
PromethazinePromethazine may increase the QTc-prolonging activities of Chloroquine.
PropacetamolThe risk or severity of adverse effects can be increased when Chloroquine is combined with Propacetamol.
PropafenoneThe serum concentration of Chloroquine can be increased when it is combined with Propafenone.
PropafenoneThe metabolism of Propafenone can be decreased when combined with Chloroquine.
PropofolPropofol may increase the QTc-prolonging activities of Chloroquine.
PropofolThe metabolism of Propofol can be decreased when combined with Chloroquine.
PropranololChloroquine may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Chloroquine.
Protein CChloroquine may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeChloroquine may increase the anticoagulant activities of Protocatechualdehyde.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Chloroquine.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Chloroquine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Chloroquine.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Chloroquine.
PTC299The risk or severity of adverse effects can be increased when Chloroquine is combined with PTC299.
PuromycinChloroquine may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PyrantelThe serum concentration of Pyrantel can be decreased when it is combined with Chloroquine.
PyrviniumThe serum concentration of Pyrvinium can be decreased when it is combined with Chloroquine.
QuetiapineChloroquine may increase the QTc-prolonging activities of Quetiapine.
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Chloroquine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Chloroquine.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Chloroquine.
QuinidineChloroquine may increase the QTc-prolonging activities of Quinidine.
QuinidineThe metabolism of Chloroquine can be decreased when combined with Quinidine.
QuinineChloroquine may increase the QTc-prolonging activities of Quinine.
QuinineThe metabolism of Chloroquine can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Chloroquine can be decreased when combined with Rabeprazole.
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Chloroquine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Chloroquine.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Chloroquine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Chloroquine.
RanolazineRanolazine may increase the QTc-prolonging activities of Chloroquine.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Chloroquine.
repinotanThe metabolism of repinotan can be decreased when combined with Chloroquine.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Chloroquine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Chloroquine.
ResveratrolThe risk or severity of adverse effects can be increased when Chloroquine is combined with Resveratrol.
ReviparinChloroquine may increase the anticoagulant activities of Reviparin.
RibostamycinChloroquine may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifabutinThe metabolism of Chloroquine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Chloroquine can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Chloroquine.
RifapentineThe metabolism of Chloroquine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Chloroquine.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Chloroquine.
RisedronateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Risedronate.
RisperidoneRisperidone may increase the QTc-prolonging activities of Chloroquine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Chloroquine.
RitonavirRitonavir may increase the QTc-prolonging activities of Chloroquine.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Chloroquine.
RivaroxabanChloroquine may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Chloroquine.
RolapitantThe metabolism of Chloroquine can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Chloroquine.
RopiniroleThe metabolism of Chloroquine can be decreased when combined with Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Chloroquine.
RosiglitazoneThe metabolism of Chloroquine can be decreased when combined with Rosiglitazone.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Chloroquine.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Chloroquine.
SalicylamideThe risk or severity of adverse effects can be increased when Chloroquine is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Salicylic acid.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Chloroquine.
SalsalateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Chloroquine.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Chloroquine.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Chloroquine.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Chloroquine.
SecobarbitalThe metabolism of Chloroquine can be increased when combined with Secobarbital.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Chloroquine.
SeratrodastThe risk or severity of adverse effects can be increased when Chloroquine is combined with Seratrodast.
SertindoleThe metabolism of Sertindole can be decreased when combined with Chloroquine.
SertralineSertraline may increase the QTc-prolonging activities of Chloroquine.
SertralineThe metabolism of Sertraline can be decreased when combined with Chloroquine.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Chloroquine.
SildenafilThe metabolism of Chloroquine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Chloroquine.
SiltuximabThe serum concentration of Chloroquine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Chloroquine can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Chloroquine.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Chloroquine.
Sodium NitriteThe risk or severity of adverse effects can be increased when Chloroquine is combined with Sodium Nitrite.
Sodium stibogluconateThe serum concentration of Sodium stibogluconate can be decreased when it is combined with Chloroquine.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Chloroquine.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Chloroquine.
SorafenibSorafenib may increase the QTc-prolonging activities of Chloroquine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Chloroquine.
SotalolChloroquine may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Chloroquine.
SparteineThe metabolism of Sparteine can be decreased when combined with Chloroquine.
SpectinomycinChloroquine may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Chloroquine.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Chloroquine.
SpironolactoneChloroquine may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Chloroquine is combined with SRT501.
St. John's WortThe serum concentration of Chloroquine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Chloroquine can be increased when it is combined with Stiripentol.
StreptomycinChloroquine may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinChloroquine may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Chloroquine.
SulfasalazineChloroquine may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Chloroquine.
SulfisoxazoleChloroquine may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Chloroquine can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Chloroquine.
SulodexideChloroquine may increase the anticoagulant activities of Sulodexide.
SunitinibSunitinib may increase the QTc-prolonging activities of Chloroquine.
SuprofenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Suprofen.
SuraminThe serum concentration of Suramin can be decreased when it is combined with Chloroquine.
TacrolimusChloroquine may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Chloroquine.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Chloroquine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Chloroquine.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Chloroquine.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Chloroquine.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Chloroquine.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Chloroquine.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Technetium Tc-99m Medronate.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Chloroquine.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Chloroquine.
TelaprevirThe metabolism of Chloroquine can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Chloroquine.
TelavancinChloroquine may increase the QTc-prolonging activities of Telavancin.
TelithromycinChloroquine may increase the QTc-prolonging activities of Telithromycin.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Chloroquine.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Chloroquine.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Chloroquine.
TenofovirThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Chloroquine.
TepoxalinThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tepoxalin.
TerbinafineThe metabolism of Chloroquine can be decreased when combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Chloroquine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Chloroquine.
TeriflunomideThe risk or severity of adverse effects can be increased when Chloroquine is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Chloroquine.
TetrabenazineChloroquine may increase the QTc-prolonging activities of Tetrabenazine.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Chloroquine.
ThiabendazoleThe serum concentration of Thiabendazole can be decreased when it is combined with Chloroquine.
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Chloroquine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Chloroquine.
ThioridazineThe metabolism of Chloroquine can be decreased when combined with Thioridazine.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Chloroquine.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tiaprofenic acid.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Chloroquine.
TiclopidineThe metabolism of Chloroquine can be decreased when combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tiludronate.
TimololChloroquine may decrease the antihypertensive activities of Timolol.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Chloroquine.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Chloroquine.
TizanidineTizanidine may increase the QTc-prolonging activities of Chloroquine.
TobramycinChloroquine may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TocilizumabThe serum concentration of Chloroquine can be decreased when it is combined with Tocilizumab.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Chloroquine.
TolterodineTolterodine may increase the QTc-prolonging activities of Chloroquine.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Chloroquine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Chloroquine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Chloroquine.
TorasemideChloroquine may decrease the diuretic activities of Torasemide.
ToremifeneChloroquine may increase the QTc-prolonging activities of Toremifene.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Chloroquine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Chloroquine.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Chloroquine.
TranilastThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tranilast.
TranylcypromineThe metabolism of Chloroquine can be decreased when combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Chloroquine.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Chloroquine.
TrazodoneTrazodone may increase the QTc-prolonging activities of Chloroquine.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Chloroquine.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Chloroquine.
TriamtereneChloroquine may decrease the antihypertensive activities of Triamterene.
TrichlorfonThe serum concentration of Trichlorfon can be decreased when it is combined with Chloroquine.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Chloroquine.
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Chloroquine.
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Chloroquine.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Chloroquine.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Chloroquine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Chloroquine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Chloroquine.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Trisalicylate-choline.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Chloroquine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Chloroquine.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Chloroquine.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Chloroquine.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Chloroquine.
VandetanibChloroquine may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Chloroquine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Chloroquine.
VemurafenibChloroquine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Chloroquine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Chloroquine.
VerapamilThe metabolism of Chloroquine can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Chloroquine.
VilanterolVilanterol may increase the QTc-prolonging activities of Chloroquine.
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Chloroquine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Chloroquine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Chloroquine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Chloroquine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Chloroquine.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Chloroquine.
VorinostatVorinostat may increase the QTc-prolonging activities of Chloroquine.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Chloroquine.
WarfarinChloroquine may increase the anticoagulant activities of Warfarin.
XimelagatranChloroquine may increase the anticoagulant activities of Ximelagatran.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Chloroquine.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Chloroquine.
ZaltoprofenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Zaltoprofen.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Chloroquine.
ZileutonThe risk or severity of adverse effects can be increased when Chloroquine is combined with Zileuton.
ZiprasidoneChloroquine may increase the QTc-prolonging activities of Ziprasidone.
ZiprasidoneThe metabolism of Chloroquine can be decreased when combined with Ziprasidone.
Zoledronic acidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Zoledronic acid.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Chloroquine.
ZomepiracThe risk or severity of adverse effects can be increased when Chloroquine is combined with Zomepirac.
ZuclopenthixolChloroquine may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Take with food to reduce irritation and increase bioavailability.

Targets

1. Fe(II)-protoporphyrin IX
Kind
Small molecule
Organism
Plasmodium falciparum
Pharmacological action
yes
Actions
antagonist
References
  1. Fitch CD: Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sci. 2004 Mar 5;74(16):1957-72. [PubMed:14967191 ]
  2. Dorn A, Vippagunta SR, Matile H, Jaquet C, Vennerstrom JL, Ridley RG: An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials. Biochem Pharmacol. 1998 Mar 15;55(6):727-36. [PubMed:9586944 ]
  3. Stoller TJ, Shields D: The propeptide of preprosomatostatin mediates intracellular transport and secretion of alpha-globin from mammalian cells. J Cell Biol. 1989 May;108(5):1647-55. [PubMed:2565905 ]
  4. Mockenhaupt FP, May J, Bergqvist Y, Meyer CG, Falusi AG, Bienzle U: Evidence for a reduced effect of chloroquine against Plasmodium falciparum in alpha-thalassaemic children. Trop Med Int Health. 2001 Feb;6(2):102-7. [PubMed:11251905 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Glutathione transferase activity
Specific Function:
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.
Gene Name:
GSTA2
Uniprot ID:
P09210
Molecular Weight:
25663.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Tumor necrosis factor receptor binding
Specific Function:
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs ...
Gene Name:
TNF
Uniprot ID:
P01375
Molecular Weight:
25644.15 Da
References
  1. Jang CH, Choi JH, Byun MS, Jue DM: Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology (Oxford). 2006 Jun;45(6):703-10. Epub 2006 Jan 17. [PubMed:16418198 ]
  2. Rachmilewitz D, Karmeli F, Shteingart S, Lee J, Takabayashi K, Raz E: Immunostimulatory oligonucleotides inhibit colonic proinflammatory cytokine production in ulcerative colitis. Inflamm Bowel Dis. 2006 May;12(5):339-45. [PubMed:16670522 ]
  3. Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A: Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus. 2006;15(5):268-75. [PubMed:16761500 ]
  4. Lim EJ, Lee SH, Lee JG, Chin BR, Bae YS, Kim JR, Lee CH, Baek SH: Activation of toll-like receptor-9 induces matrix metalloproteinase-9 expression through Akt and tumor necrosis factor-alpha signaling. FEBS Lett. 2006 Aug 7;580(18):4533-8. Epub 2006 Jul 17. [PubMed:16870179 ]
  5. Dias-Melicio LA, Calvi SA, Bordon AP, Golim MA, Peracoli MT, Soares AM: Chloroquine is therapeutic in murine experimental model of paracoccidioidomycosis. FEMS Immunol Med Microbiol. 2007 Jun;50(1):133-43. Epub 2007 Apr 23. [PubMed:17456179 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transmembrane signaling receptor activity
Specific Function:
Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR9 is a nucleotide-sensing TLR which is activated by unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the i...
Gene Name:
TLR9
Uniprot ID:
Q9NR96
Molecular Weight:
115858.665 Da
References
  1. Trevani AS, Chorny A, Salamone G, Vermeulen M, Gamberale R, Schettini J, Raiden S, Geffner J: Bacterial DNA activates human neutrophils by a CpG-independent pathway. Eur J Immunol. 2003 Nov;33(11):3164-74. [PubMed:14579285 ]
  2. Rutz M, Metzger J, Gellert T, Luppa P, Lipford GB, Wagner H, Bauer S: Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol. 2004 Sep;34(9):2541-50. [PubMed:15307186 ]
  3. Lenert P: Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases? Clin Exp Immunol. 2005 Apr;140(1):1-10. [PubMed:15762869 ]
  4. Huang LY, Ishii KJ, Akira S, Aliberti J, Golding B: Th1-like cytokine induction by heat-killed Brucella abortus is dependent on triggering of TLR9. J Immunol. 2005 Sep 15;175(6):3964-70. [PubMed:16148144 ]
  5. Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW, Selander KS: Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res. 2006 Jul;4(7):437-47. [PubMed:16849519 ]
Kind
Protein
Organism
Plasmodium falciparum
Pharmacological action
unknown
General Function:
Glutathione transferase activity
Specific Function:
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. May also function as a storage protein or ligandin for parasitotoxic ferriprotoporphyrin IX (hemin).
Gene Name:
GST
Uniprot ID:
Q8MU52
Molecular Weight:
24788.9 Da
References
  1. Hiller N, Fritz-Wolf K, Deponte M, Wende W, Zimmermann H, Becker K: Plasmodium falciparum glutathione S-transferase--structural and mechanistic studies on ligand binding and enzyme inhibition. Protein Sci. 2006 Feb;15(2):281-9. Epub 2005 Dec 29. [PubMed:16385005 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23